-
Je něco špatně v tomto záznamu ?
Aberrant expression of the microRNA cluster in 14q32 is associated with del(5q) myelodysplastic syndrome and lenalidomide treatment
Z. Krejčík, M. Beličková, A. Hruštincová, J. Kléma, Z. Zemanová, K. Michalová, J. Čermák, A. Jonášová, M. Dostálová Merkerová,
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články, práce podpořená grantem
Grantová podpora
NT13847
MZ0
CEP - Centrální evidence projektů
- MeSH
- chromozomální delece MeSH
- imunologické faktory terapeutické užití MeSH
- inhibitory angiogeneze terapeutické užití MeSH
- lidé MeSH
- lidské chromozomy, pár 14 genetika MeSH
- lidské chromozomy, pár 5 genetika MeSH
- mikro RNA genetika MeSH
- myelodysplastické syndromy farmakoterapie genetika MeSH
- regulace genové exprese u nádorů MeSH
- sekvenční analýza hybridizací s uspořádaným souborem oligonukleotidů MeSH
- sekvenční delece MeSH
- stanovení celkové genové exprese MeSH
- studie případů a kontrol MeSH
- thalidomid analogy a deriváty terapeutické užití MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
Lenalidomide is a novel thalidomide analogue with immunomodulatory and antiangiogenic effects that has been successfully used for the treatment of low and intermediate-1 risk myelodysplastic syndromes (MDSs) with a del(5q) aberration. Because information about the influence of lenalidomide on the microRNA (miRNA) transcriptome is limited, we performed miRNA expression profiling of bone marrow CD34+ cells obtained from MDS patients with the del(5q) abnormality who had been subjected to lenalidomide treatment. To define differences in miRNA expression, we performed paired data analysis to compare the miRNA profiles of patients before and during lenalidomide treatment and those of healthy donors. The analysis showed that miRNAs clustering to the 14q32 region had a higher expression level in patient samples before treatment than in the healthy control samples, and this elevated expression was diminished following lenalidomide administration. Because some of the 14q32 miRNAs play important roles in hematopoiesis, stem cell differentiation, and apoptosis induction, the expression of this cluster may be associated with the pathophysiology of the disease.
1st Department of Medicine General University Hospital Prague Czech Republic
Institute of Hematology and Blood Transfusion Prague Czech Republic
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc15031387
- 003
- CZ-PrNML
- 005
- 20191029105215.0
- 007
- ta
- 008
- 151005s2015 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.cancergen.2015.03.003 $2 doi
- 035 __
- $a (PubMed)25883014
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Krejčík, Zdeněk $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic. $7 xx0125786
- 245 10
- $a Aberrant expression of the microRNA cluster in 14q32 is associated with del(5q) myelodysplastic syndrome and lenalidomide treatment / $c Z. Krejčík, M. Beličková, A. Hruštincová, J. Kléma, Z. Zemanová, K. Michalová, J. Čermák, A. Jonášová, M. Dostálová Merkerová,
- 520 9_
- $a Lenalidomide is a novel thalidomide analogue with immunomodulatory and antiangiogenic effects that has been successfully used for the treatment of low and intermediate-1 risk myelodysplastic syndromes (MDSs) with a del(5q) aberration. Because information about the influence of lenalidomide on the microRNA (miRNA) transcriptome is limited, we performed miRNA expression profiling of bone marrow CD34+ cells obtained from MDS patients with the del(5q) abnormality who had been subjected to lenalidomide treatment. To define differences in miRNA expression, we performed paired data analysis to compare the miRNA profiles of patients before and during lenalidomide treatment and those of healthy donors. The analysis showed that miRNAs clustering to the 14q32 region had a higher expression level in patient samples before treatment than in the healthy control samples, and this elevated expression was diminished following lenalidomide administration. Because some of the 14q32 miRNAs play important roles in hematopoiesis, stem cell differentiation, and apoptosis induction, the expression of this cluster may be associated with the pathophysiology of the disease.
- 650 _2
- $a inhibitory angiogeneze $x terapeutické užití $7 D020533
- 650 _2
- $a studie případů a kontrol $7 D016022
- 650 _2
- $a chromozomální delece $7 D002872
- 650 _2
- $a lidské chromozomy, pár 14 $x genetika $7 D002883
- 650 _2
- $a lidské chromozomy, pár 5 $x genetika $7 D002895
- 650 _2
- $a stanovení celkové genové exprese $7 D020869
- 650 _2
- $a regulace genové exprese u nádorů $7 D015972
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a imunologické faktory $x terapeutické užití $7 D007155
- 650 _2
- $a mikro RNA $x genetika $7 D035683
- 650 _2
- $a myelodysplastické syndromy $x farmakoterapie $x genetika $7 D009190
- 650 _2
- $a sekvenční analýza hybridizací s uspořádaným souborem oligonukleotidů $7 D020411
- 650 _2
- $a sekvenční delece $7 D017384
- 650 _2
- $a thalidomid $x analogy a deriváty $x terapeutické užití $7 D013792
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Beličková, Monika $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic. $7 xx0099634
- 700 1_
- $a Hruštincová, Andrea. $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic. $7 xx0242102
- 700 1_
- $a Kléma, Jiří, $u Department of Computer Science, Faculty of Electrical Engineering, Czech Technical University, Prague, Czech Republic. $d 1971- $7 ntka172916
- 700 1_
- $a Zemanová, Zuzana, $u Center of Oncocytogenetics, General University Hospital and First Faculty of Medicine, Charles University, Prague, Czech Republic. $d 1962- $7 nlk20050170627
- 700 1_
- $a Michalová, Kyra, $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic; Center of Oncocytogenetics, General University Hospital and First Faculty of Medicine, Charles University, Prague, Czech Republic. $d 1942- $7 nlk19990073558
- 700 1_
- $a Čermák, Jaroslav, $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic. $d 1954- $7 xx0053072
- 700 1_
- $a Jonášová, Anna $u First Department of Medicine, General University Hospital, Prague, Czech Republic. $7 xx0103767
- 700 1_
- $a Dostálová, Michaela $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic. Electronic address: michaela.merkerova@uhkt.cz. $7 xx0164071
- 773 0_
- $w MED00180193 $t Cancer genetics $x 2210-7762 $g Roč. 208, č. 4 (2015), s. 156-161
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/25883014 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20151005 $b ABA008
- 991 __
- $a 20191029105654 $b ABA008
- 999 __
- $a ok $b bmc $g 1092263 $s 914513
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2015 $b 208 $c 4 $d 156-161 $e 20150312 $i 2210-7762 $m Cancer genetics $n Cancer Genet $x MED00180193
- GRA __
- $a NT13847 $p MZ0
- LZP __
- $a Pubmed-20151005
